This cluster is routine and non-informative. The sales are small relative to market cap, all tied to option exercises, and consistent with standard cashless exercise patterns. No bearish signal. Monitor the next 8-K or earnings release for any fundamental changes, but this filing alone does not warrant action.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $164.23entry
- T+1 · 6mo ago +1.58%α +1.18% · $166.83
- T+5 · 5mo ago −2.05%α +1.77% · $160.86
- T+20 · 5mo ago +2.16%α +3.28% · $167.77
- T+60 · 3mo ago −5.36%α −7.59% · $155.43
Price Chart
How similar events traded
Executive Summary
Three NBIX insiders, including the Chief Scientific Officer, sold a combined $2.67M in open-market shares over a 4-day window. All sales were preceded by option exercises at zero or low cost, indicating routine cashless exercises rather than opportunistic bearish bets. The total value represents ~0.016% of NBIX's $16.2B market cap, a trivial amount with no material signaling value.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $2.67M in open-market shares between May 26-29, 2026
- Chief Scientific Officer Onyia Jude sold $1.71M (11,000 shares at $155.53) after exercising options at $84.74
- Chief Corp. Affairs Officer Boyer David W. sold $609K (3,890 shares at $156.64)
- Chief Regulatory Officer Delaet Ingrid sold $354K (2,261 shares at $156.71) after exercising options at $79.02
- Total sales equal ~0.016% of NBIX's $16.2B market cap, well below the 0.1% materiality threshold
- All sales were preceded by option exercises, consistent with routine cashless exercises for tax/vesting purposes
- No open-market purchases were made by any insider during the window
Financial Impact
$2.67M in insider sales, representing 0.016% of market cap
Risk Factors
- Insiders may continue selling if the stock appreciates further, but no evidence of coordinated bearish view
- No purchases to offset the selling, but the dollar amounts are too small to infer negative sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780437825000 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers